HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
To evaluate the safety and efficacy of HRS-4642 in Combination With AG and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
Trial Details
- NCT ID
- NCT07131514
- Phase
- PHASE2
- Sponsor
- Ruijin Hospital
- Status
- RECRUITING
- Cancer Type
- Pancreatic Cancer
- Interventions
- Locations (sample)
- Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
- Age: ≥18 and ≤80 years old, male or female;
- Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined b…
- Imaging evaluation met the NCCN guidelines definition of resectable pancreatic cancer (including high-risk resectable) and borderline resectable pa…
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;
For full eligibility, visit ClinicalTrials.gov.